Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity

PLoS Neglected Tropical Diseases

Volumn 11, Issue 7, 2017, Pages

  Doyle, Stephen R ^a,b   Bourguinat, Catherine ^c   Nana Djeunga, Hugues C ^d,e   Kengne Ouafo, Jonas A ^f   Pion, Sébastien D S ^g   Bopda, Jean ^d   Kamgno, Joseph ^d,e   Wanji, Samuel ^f   Che, Hua ^c   Kuesel, Annette C ^h   Walker, Martin ^i,l   Basáñez, Maria Gloria ⁱ   Boakye, Daniel A ^j   Osei Atweneboana, Mike Y ^k   Boussinesq, Michel ^g   Prichard, Roger K ^c   Grant, Warwick N ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^e Centre for Research on Filariasis and other Tropical Diseases (CRFilMT)   (Cameroon)

^f Research Foundation in Tropical Diseases and Environment (REFOTDE)   (Cameroon)

^g INSERM   (France)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j University of Ghana   (Ghana)

^k CSIR WATER RESEARCH INSTITUTE   (Ghana)

^l ROYAL VETERINARY COLLEGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN; IVERMECTIN; MYOSIN; NOTCH RECEPTOR; ANTIPARASITIC AGENT;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DNA EXTRACTION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE; GENE AMPLIFICATION; GENETIC DRIFT; GENETIC VARIABILITY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GEOGRAPHY; MICROFILARIA (NEMATODE LARVA); NEUROTRANSMISSION; NEXT GENERATION SEQUENCING; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; OVO ABCF 1 GENE; PARASITE; POPULATION DIFFERENTIATION; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE TRAIT LOCUS; SELECTIVE SWEEP; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CAMEROON; CLASSIFICATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; GHANA; HIGH THROUGHPUT SEQUENCING; HUMAN; PARASITOLOGY;

ANIMALS; ANTIPARASITIC AGENTS; CAMEROON; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETIC DRIFT; GENETIC VARIATION; GENOTYPE; GHANA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IVERMECTIN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; QUANTITATIVE TRAIT LOCI;

EID: 85026752157     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005816     Document Type: Article

References (114)

1. Remme JHF, Boatin B, Boussinesq M, SR Q, WC C, Helminthic Diseases: Onchocerciasis and Loiasis. In: The International Encyclopedia of Public Health. Vol. 3. 2nd ed. Oxford: Elsevier; 2016. p. 576–87.
2. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga N, Duke BO, Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360(9328):203–10. doi: 10.1016/S0140-6736(02)09456-4 12133654
3. Duke BO, Zea-Flores G, Castro J, Cupp EW, Munoz B, Effects of multiple monthly doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1990;43(6):657–64. 2267970
4. Kläger SL, Whitworth JA, Downham MD, Viability and fertility of adult Onchocerca volvulus after 6 years of treatment with ivermectin. Trop Med Int Health. 1996;1(5):581–9. 8911442
5. Basáñez MG, Pion SDS, Boakes E, Filipe JA, Churcher TS, Boussinesq M, Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(5):310–22. doi: 10.1016/S1473-3099(08)70099-9 18471776
6. Rodriguez-Perez MA, Unnasch TR, Dominguez-Vazquez A, Morales-Castro AL, Pena-Flores GP, Orozco-Algarra ME, et al. Interruption of transmission of Onchocerca volvulus in the Oaxaca focus, Mexico. Am J Trop Med Hyg. 2010;83(1):21–7. doi: 10.4269/ajtmh.2010.09-0544 20595472
7. Rodriguez-Perez MA, Dominguez-Vazquez A, Unnasch TR, Hassan HK, Arredondo-Jimenez JI, Orozco-Algarra ME, et al. Interruption of transmission of Onchocerca volvulus in the Southern Chiapas Focus, Mexico. PLoS Negl Trop Dis. 2013;7(3):e2133. doi: 10.1371/journal.pntd.0002133 23556018
8. Gonzalez RJ, Cruz-Ortiz N, Rizzo N, Richards J, Zea-Flores G, Dominguez A, et al. Successful interruption of transmission of Onchocerca volvulus in the Escuintla-Guatemala focus, Guatemala. PLoS Negl Trop Dis. 2009;3(3):e404. doi: 10.1371/journal.pntd.0000404 19333366
9. Lovato R, Guevara A, Guderian R, Proano R, Unnasch T, Criollo H, et al. Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution. PLoS Negl Trop Dis. 2014;8(5):e2821. doi: 10.1371/journal.pntd.0002821 24853587
10. Convit J, Schuler H, Borges R, Olivero V, Dominguez-Vazquez A, Frontado H, et al. Interruption of Onchocerca volvulus transmission in Northern Venezuela. Parasit Vectors. 2013;6(1):289. doi: 10.1186/1756-3305-6-289 24499653
11. Richards F, Jr.Rizzo N, Diaz Espinoza CE, Monroy ZM, Crovella Valdez CG, de Cabrera RM, et al. One hundred years after its discovery in Guatemala by Rodolfo Robles, Onchocerca volvulus transmission has been eliminated from the central endemic zone. Am J Trop Med Hyg. 2015;93(6):1295–304. doi: 10.4269/ajtmh.15-0364 26503275
12. Botto C, Basañez MG, Escalona M, Villamizar NJ, Noya-Alarcón O, Cortez J, et al. Evidence of suppression of onchocerciasis transmission in the Venezuelan Amazonian focus. Parasit Vectors. 2016;9(1):40.
13. Higazi TB, Zarroug IM, Mohamed HA, Elmubark WA, Deran TC, Aziz N, et al. Interruption of Onchocerca volvulus transmission in the Abu Hamed focus, Sudan. Am J Trop Med Hyg. 2013;89(1):51–7. doi: 10.4269/ajtmh.13-0112 23690554
14. Katabarwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, Oguttu DW, et al. Transmission of onchocerciasis in wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. J Parasitol Res. 2012;2012:748540. doi: 10.1155/2012/748540 22970347
15. Lakwo TL, Garms R, Rubaale T, Katabarwa M, Walsh F, Habomugisha P, et al. The disappearance of onchocerciasis from the Itwara focus, western Uganda after elimination of the vector Simulium neavei and 19 years of annual ivermectin treatments. Acta Trop. 2013;126(3):218–21. doi: 10.1016/j.actatropica.2013.02.016 23458325
16. Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasit Vectors. 2012;5:28. doi: 10.1186/1756-3305-5-28 22313631
17. Tekle AH, Zoure HG, Noma M, Boussinesq M, Coffeng LE, Stolk WA, et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infect Dis Poverty. 2016;5(1):66. doi: 10.1186/s40249-016-0160-7 27349645
18. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6(9):e1825. doi: 10.1371/journal.pntd.0001825 23029586
19. Zarroug IM, Hashim K, ElMubark WA, Shumo ZA, Salih KA, ElNojomi NA, et al. The first confirmed elimination of an onchocerciasis focus in Africa: Abu Hamed, Sudan. Am J Trop Med Hyg. 2016.
20. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation. Geneva: World Health Organization; 2012.
21. Eighteenth session of the Joint Action Forum (JAF) of the African Programme for Onchocerciasis Control, Bujumbura, Burundi, 11–13 December 2012. Final communiqué. Africa Programme for Onchocerciasis Control (APOC); 2012.
22. Borsboom GJ, Boatin BA, Nagelkerke NJ, Agoua H, Akpoboua KL, Alley EW, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J. 2003;2(1):8. doi: 10.1186/1475-2883-2-8 12769825
23. Remme J, Baker RH, De Sole G, Dadzie KY, Walsh JF, Adams MA, et al. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulus. Trop Med Parasitol. 1989;40(3):367–74. 2617046
24. Lakwo TL, Preliminary studies on the biting activity and transmission of Onchocerca volvulus by Simulium neavei (diptera: simuliidae) in Kashoya-Kitomi focus, Western Uganda. East Afr Med J. 2004;81(5):244–7. 15508338
25. Katabarwa M, Eyamba A, Habomugisha P, Lakwo T, Ekobo S, Kamgno J, et al. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues. Trop Med Int Health. 2008;13(9):1196–203. doi: 10.1111/j.1365-3156.2008.02126.x 18631308
26. Katabarwa MN, Eyamba A, Nwane P, Enyong P, Yaya S, Baldiagai J, et al. Seventeen years of annual distribution of ivermectin has not interrupted onchocerciasis transmission in North Region, Cameroon. Am J Trop Med Hyg. 2011;85(6):1041–9. doi: 10.4269/ajtmh.2011.11-0333 22144441
27. Frempong KK, Walker M, Cheke RA, Tetevi EJ, Gyan ET, Owusu EO, et al. Does increasing treatment frequency address suboptimal responses to ivermectin for the control and elimination of River Blindness?Clin Infect Dis. 2016;62(11):1338–47. doi: 10.1093/cid/ciw144 27001801
28. Eisenbarth A, Achukwi MD, Renz A, Ongoing transmission of Onchocerca volvulus after 25 years of annual ivermectin mass treatments in the Vina du Nord River Valley, in North Cameroon. PLoS Negl Trop Dis. 2016;10(2):e0004392. doi: 10.1371/journal.pntd.0004392 26926855
29. Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98(4):359–70. doi: 10.1179/000349804225003442 15228717
30. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98(3):231–49. doi: 10.1179/000349804225003253 15119969
31. Lamberton PHL, Cheke RA, Winskill P, Tirados I, Walker M, Osei-Atweneboana MY, et al. Onchocerciasis Transmission in Ghana: Persistence under Different Control Strategies and the Role of the Simuliid Vectors. PLoS Negl Trop Dis. 2015;9(4):e0003688. doi: 10.1371/journal.pntd.0003688 25897492
32. Kamga G-R, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Mbigha-Ghogomu S, Souopgui J, et al. Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Parasit Vectors. 2016;9(1):581. doi: 10.1186/s13071-016-1868-8 27842567
33. Koala L, Nikiema A, Post RJ, Paré AB, Kafando CM, Drabo F, et al. Recrudescence of onchocerciasis in the Comoé valley in Southwest Burkina Faso. Acta Tropica. 2017;166:96–105. doi: 10.1016/j.actatropica.2016.11.003 27845063
34. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK, Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011;5(3):e998. doi: 10.1371/journal.pntd.0000998 21468315
35. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK, Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369(9578):2021–9. doi: 10.1016/S0140-6736(07)60942-8 17574093
36. Pion SDS, Nana-Djeunga HC, Kamgno J, Tendongfor N, Wanji S, Njiokou F, et al. Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naive and a multiply treated population from Cameroon. PLoS Negl Trop Dis. 2013;7(2):e2084. doi: 10.1371/journal.pntd.0002084 23469307
37. Nana-Djeunga HC, Bourguinat C, Pion SDS, Bopda J, Kengne-Ouafo JA, Njiokou F, et al. Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naive and a frequently treated population from Cameroon. PLoS Negl Trop Dis. 2014;8(4):e2824. doi: 10.1371/journal.pntd.0002824 24762816
38. Osei-Atweneboana MY, Boakye DA, Awadzi K, Gyapong JO, Prichard RK, Genotypic analysis of beta-tubulin in Onchocerca volvulus from communities and individuals showing poor parasitological response to ivermectin treatment. Int J Parasitol Drugs Drug Resist. 2012;2.
39. Ardelli BF, Guerriero SB, Prichard RK, Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol Biochem Parasitol. 2005;143(1):58–66. doi: 10.1016/j.molbiopara.2005.05.006 15993957
40. Ardelli BF, Guerriero SB, Prichard RK, Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus: linkage disequilibrium and genotype diversity. Parasitology. 2006;132(Pt 3):375–86. doi: 10.1017/S0031182005008991 16280093
41. Ardelli BF, Guerriero SB, Prichard RK, Characterization of a half-size ATP-binding cassette transporter gene which may be a useful marker for ivermectin selection in Onchocerca volvulus. Mol Biochem Parasitol. 2006;145(1):94–100. doi: 10.1016/j.molbiopara.2005.09.011 16257066
42. Ardelli BF, Prichard RK, Identification of variant ABC-transporter genes among Onchocerca volvulus collected from ivermectin-treated and untreated patients in Ghana, West Africa. Ann Trop Med Parasitol. 2004;98(4):371–84. doi: 10.1179/000349804225003415 15228718
43. Ardelli BF, Prichard RK, Reduced genetic variation of an Onchocerca volvulus ABC transporter gene following treatment with ivermectin. Trans R Soc Trop Med Hyg. 2007;101(12):1223–32. doi: 10.1016/j.trstmh.2005.03.019 17904599
44. Bourguinat C, Ardelli BF, Pion SD, Kamgno J, Gardon J, Duke BO, P-glycoprotein-like protein, a possible genetic marker for ivermectin resistance selection in Onchocerca volvulus. Mol Biochem Parasitol. 2008;158.
45. Bottomley C, Isham V, Collins RC, Basáñez MG, Rates of microfilarial production by Onchocerca volvulus are not cumulatively reduced by multiple ivermectin treatments. Parasitology. 2008;135(13):1571–81. doi: 10.1017/S0031182008000425 18831801
46. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC, A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953. doi: 10.1371/journal.pntd.0002953 24968000
47. Bakajika DK, Kanza E, Howard H, Opoku N, Tchatchu J-PL, Kataliko K, et al., editors. Is O. volvulus suboptimal response to ivermectin a result of selection under ivermectin pressure? Insights from a study comparing ivermectin and moxidectin in areas without prior ivermectin mass treatment. Am J Trop Med Hyg; 2013; Washington, DC.
48. Pion SDS, Grout L, Kamgno J, Nana-Djeunga H, Boussinesq M, Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Trop. 2011;120Suppl 1:S91–9.
49. Burnham G, Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370(9593):1125.
50. Cupp E, Richards F, Lammie P, Eberhard M, Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370(9593):1123; author reply 4–5.
51. Mackenzie CD, Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370(9593):1123; author reply 4–5.
52. Remme JH, Amazigo U, Engels D, Barryson A, Yameogo L, Efficacy of ivermectin against Onchocerca volvulus in Ghana. Lancet. 2007;370(9593):1123–4; author reply 4–5.
53. Hotez PJ, Control of onchocerciasis—the next generation. Lancet. 2007;369(9578):1979–80. doi: 10.1016/S0140-6736(07)60923-4 17574078
54. Churcher TS, Pion SDS, Osei-Atweneboana MY, Prichard RK, Awadzi K, Boussinesq M, et al. Identifying sub-optimal responses to ivermectin in the treatment of river blindness. Proc Natl Acad Sci U S A. 2009;106(39):16716–21. doi: 10.1073/pnas.0906176106 19805362
55. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG, Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. PLoS Negl Trop Dis. 2013;7(4):e2169. doi: 10.1371/journal.pntd.0002169 23634234
56. Park DJ, Lukens AK, Neafsey DE, Schaffner SF, Chang HH, Valim C, et al. Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc Natl Acad Sci U S A. 2012;109(32):13052–7. doi: 10.1073/pnas.1210585109 22826220
57. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major genome region underlying artemisinin resistance in malaria. Science. 2012;336(6077):79–82. doi: 10.1126/science.1215966 22491853
58. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013;45(6):648–55. doi: 10.1038/ng.2624 23624527
59. Cheeseman IH, McDew-White M, Phyo AP, Sriprawat K, Nosten F, Anderson TJ, Pooled sequencing and rare variant association tests for identifying the determinants of emerging drug resistance in malaria parasites. Mol Biol Evol. 2015;32(4):1080–90. doi: 10.1093/molbev/msu397 25534029
60. Chang H-H, Moss EL, Park DJ, Ndiaye D, Mboup S, Volkman SK, et al. Malaria life cycle intensifies both natural selection and random genetic drift. Proceedings of the National Academy of Sciences. 2013;110(50):20129–34.
61. Valentim CL, Cioli D, Chevalier FD, Cao X, Taylor AB, Holloway SP, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science. 2013;342(6164):1385–9. doi: 10.1126/science.1243106 24263136
62. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, et al. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 2011;21(12):2143–56. doi: 10.1101/gr.123430.111 22038251
63. Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill FX, Goodhead I, et al. High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi. Nat Genet. 2008;40(8):987–93. doi: 10.1038/ng.195 18660809
64. Gilleard JS, Understanding anthelmintic resistance: The need for genomics and genetics. Int J Parasitol. 2006;36(12):1227–39. doi: 10.1016/j.ijpara.2006.06.010 16889782
65. Kotze AC, Hunt PW, Skuce P, von Samson-Himmelstjerna G, Martin RJ, Sager H, et al. Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions. Int J Parasitol Drugs Drug Resist. 2014;4(3):164–84. doi: 10.1016/j.ijpddr.2014.07.007 25516826
66. Choi Y-J, Tyagi R, McNulty SN, Rosa BA, Ozersky P, Martin J, et al. Genomic diversity in Onchocerca volvulus and its Wolbachia endosymbiont. Nat Microbiol. 2016;2:16207. doi: 10.1038/nmicrobiol.2016.207 27869792
67. Meredith SEO, Lando G, Gbakima AA, Zimmerman PA, Unnasch TR, Onchocerca volvulus—Application of the Polymerase Chain-Reaction to Identification and Strain Differentiation of the Parasite. Exp Parasitol. 1991;73(3):335–44. 1915748
68. Zimmerman PA, Dadzie KY, Desole G, Remme J, Alley ES, Unnasch TR, Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness. J Infect Dis. 1992;165(5):964–8. 1569351
69. Bottomley C, Isham V, Vivas-Martínez S, Kuesel AC, Attah SK, Opoku NO, et al. Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for Onchocerca volvulus in near elimination and surveillance settings. Parasit Vectors. 2016;9(1):343. doi: 10.1186/s13071-016-1605-3 27301567
70. Cotton JA, Bennuru S, Grote A, Harsha B, Tracey A, Beech R, et al. The genome of Onchocerca volvulus, agent of river blindness. Nat Microbiol. 2016;2:16216. doi: 10.1038/nmicrobiol.2016.216 27869790
71. Bennuru S, Cotton JA, Ribeiro JM, Grote A, Harsha B, Holroyd N, et al. Stage-specific transcriptome and proteome analyses of the filarial parasite Onchocerca volvulus and its Wolbachia endosymbiont. MBio. 2016;7(6).
72. Howe KL, Bolt BJ, Shafie M, Kersey P, Berriman M, WormBase ParaSite − a comprehensive resource for helminth genomics. Mol Biochem Parasitol. 2016;In press: Available online 27 November 2016.
73. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv:13033997. 2013.
74. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8. doi: 10.1038/ng.806 21478889
75. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303. doi: 10.1101/gr.107524.110 20644199
76. Bansal V, A statistical method for the detection of variants from next-generation resequencing of DNA pools. Bioinformatics. 2010;26(12):i318–24. doi: 10.1093/bioinformatics/btq214 20529923
77. Kofler R, Pandey RV, Schlötterer C, PoPoolation2: identifying differentiation between populations using sequencing of pooled DNA samples (Pool-Seq). Bioinformatics. 2011;27(24):3435–6. doi: 10.1093/bioinformatics/btr589 22025480
78. Storm N, Darnhofer-Patel B, van den Boom D, Rodi CP, MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol. 2003;212:241–62. 12491915
79. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. doi: 10.1086/519795 17701901
80. Jombart T, adegenet: a R package for the multivariate analysis of genetic markers. Bioinformatics. 2008;24(11):1403–5. doi: 10.1093/bioinformatics/btn129 18397895
81. Duke BO, The population dynamics of Onchocerca volvulus in the human host. Trop Med Parasitol. 1993;44(2):61–8. 8367667
82. Duerr HP, Dietz K, Schulz-Key H, Buttner DW, Eichner M, The relationships between the burden of adult parasites, host age and the microfilarial density in human onchocerciasis. Int J Parasitol. 2004;34(4):463–73. doi: 10.1016/j.ijpara.2003.11.008 15013736
83. Rellstab C, Zoller S, Tedder A, Gugerli F, Fischer MC, Validation of SNP allele frequencies determined by pooled next-generation sequencing in natural populations of a non-model plant species. PLoS One. 2013;8(11):e80422. doi: 10.1371/journal.pone.0080422 24244686
84. Kim SY, Li Y, Guo Y, Li R, Holmkvist J, Hansen T, et al. Design of association studies with pooled or un-pooled next-generation sequencing data. Genet Epidemiol. 2010;34(5):479–91. doi: 10.1002/gepi.20501 20552648
85. Futschik A, Schlötterer C, The next generation of molecular markers from massively parallel sequencing of pooled DNA samples. Genetics. 2010;186(1):207–18. doi: 10.1534/genetics.110.114397 20457880
86. Schlötterer C, Tobler R, Kofler R, Nolte V, Sequencing pools of individuals—mining genome-wide polymorphism data without big funding. Nat Rev Genet. 2014;15(11):749–63. doi: 10.1038/nrg3803 25246196
87. Anderson EC, Skaug HJ, Barshis DJ, Next-generation sequencing for molecular ecology: a caveat regarding pooled samples. Mol Ecol. 2014;23(3):502–12. doi: 10.1111/mec.12609 24304095
88. Lynch M, Bost D, Wilson S, Maruki T, Harrison S, Population-genetic inference from pooled-sequencing data. Genome Biol Evol. 2014;6(5):1210–8. doi: 10.1093/gbe/evu085 24787620
89. Kofler R, Orozco-terWengel P, De Maio N, Pandey RV, Nolte V, Futschik A, et al. PoPoolation: a toolbox for population genetic analysis of next generation sequencing data from pooled individuals. PLoS One. 2011;6(1):e15925. doi: 10.1371/journal.pone.0015925 21253599
90. Traore-Lamizana M, Lemasson J, Participation à une étude de faisabilité d'une campagne de lutte contre l'onchocercose dans la région du bassin du Logone: répartition des espèces du complexe Simulium damnosum dans la zone camerounaise du projet. Cahiers-ORSTOM Entomologie médicale et parasitologie. 1988;25(3–4):171–86.
91. Basáñez MG, Churcher TS, Grillet ME, Onchocerca-Simulium interactions and the population and evolutionary biology of Onchocerca volvulus. Adv Parasitol. 2009;68.
92. Cully DF, Vassilatis DK, Liu KK, Paress PS, Vanderploeg LHT, Schaeffer JM, et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature. 1994;371(6499):707–11. doi: 10.1038/371707a0 7935817
93. Bany IA, Dong MQ, Koelle MR, Genetic and cellular basis for acetylcholine inhibition of Caenorhabditis elegans egg-laying behavior. J Neurosci. 2003;23(22):8060–9. 12954868
94. Ringstad N, Horvitz HR, FMRFamide neuropeptides and acetylcholine synergistically inhibit egg-laying by C. elegans. Nat Neurosci. 2008;11(10):1168–76. doi: 10.1038/nn.2186 18806786
95. Waggoner LE, Zhou GT, Schafer RW, Schafer WR, Control of alternative behavioral states by serotonin in Caenorhabditis elegans. Neuron. 1998;21(1):203–14. 9697864
96. Li B-W, Rush AC, Weil GJ, Expression of five acetylcholine receptor subunit genes in Brugia malayi adult worms. Int J Parasitol Drugs Drug Resist. 2015;5(3):100–9. doi: 10.1016/j.ijpddr.2015.04.003 26199859
97. Hernando G, Bouzat C, Caenorhabditis elegans neuromuscular junction: GABA receptors and ivermectin action. PLoS One. 2014;9(4):e95072. doi: 10.1371/journal.pone.0095072 24743647
98. Abongwa M, Buxton SK, Robertson AP, Martin RJ, Curiouser and curiouser: The macrocyclic lactone, abamectin, is also a potent inhibitor of pyrantel/tribendimidine nicotinic acetylcholine receptors of gastro-intestinal worms. PLoS One. 2016;11(1).
99. Bourguinat C, Pion SDS, Kamgno J, Gardon J, Duke BOL, Boussinesq M, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis. 2007;1(1).
100. Laing ST, Ivens A, Butler V, Ravikumar SP, Laing R, Woods DJ, et al. The transcriptional response of Caenorhabditis elegans to Ivermectin exposure identifies novel genes involved in the response to reduced food intake. PLoS One. 2012;7(2):e31367. doi: 10.1371/journal.pone.0031367 22348077
101. Bourguinat C, Lee AC, Lizundia R, Blagburn BL, Liotta JL, Kraus MS, et al. Macrocyclic lactone resistance in Dirofilaria immitis: Failure of heartworm preventives and investigation of genetic markers for resistance. Vet Parasitol. 2015;210(3–4):167–78. doi: 10.1016/j.vetpar.2015.04.002 25936435
102. Choi YJ, Bisset SA, Doyle SR, Hallsworth-Pepin K, Martin J, Grant WN, et al. Genomic introgression mapping of field-derived multiple-anthelmintic resistance in the nematode parasite Teladorsagia circumcincta. PLoS Genet. 2017;13,e1006857
103. Bourguinat C, Keller K, Blagburn B, Schenker R, Geary TG, Prichard RK, Correlation between loss of efficacy of macrocyclic lactone heartworm anthelmintics and P-glycoprotein genotype. Vet Parasitol. 2011;176(4):374–81. doi: 10.1016/j.vetpar.2011.01.024 21300438
104. Hunt PW. Identification and characterisation of dominant ivermectin resistant genes in Caenorhabditis elegans [PhD thesis]: University of New England; 1995.
105. Barnes TM, Hekimi S, The Caenorhabditis elegans avermectin resistance and anesthetic response gene unc-9 encodes a member of a protein family implicated in electrical coupling of excitable cells. J Neurochem. 1997;69(6):2251–60. 9375655
106. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: An economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis. 2014;59(7):923–32. doi: 10.1093/cid/ciu467 24944228
107. Stolk WA, Walker M, Coffeng LE, Basáñez MG, de Vlas SJ, Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasit Vectors. 2015;8(1):552.
108. Coffeng LE, Stolk WA, Hoerauf A, Habbema D, Bakker R, Hopkins AD, et al. Elimination of African onchocerciasis: Modeling the impact of increasing the frequency of ivermectin mass treatment. PLoS One. 2015;9(12):e115886.
109. Doyle SR, Armoo S, Renz A, Taylor MJ, Osei-Atweneboana MY, Grant WN, Discrimination between Onchocerca volvulus and O. ochengi filarial larvae in Simulium damnosum (s.l.) and their distribution throughout central Ghana using a versatile high-resolution speciation assay. Parasit Vectors. 2016;9(1):536. doi: 10.1186/s13071-016-1832-7 27724959
110. Taylor MJ, Hoerauf A, Townson S, Slatko BE, Ward SA, Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology. 2014;141(1):119–27. doi: 10.1017/S0031182013001108 23866958
111. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG, Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clinical Infectious Diseases. 2015;60(8):1199–207. doi: 10.1093/cid/ciu1152 25537873
112. Turner HC, Walker M, Attah SK, Opoku NO, Awadzi K, Kuesel AC, et al. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data. Parasit Vectors. 2015;8(1):167.
113. Kuesel AC, Research for new drugs for elimination of onchocerciasis in Africa. Int J Parasitol Drugs Drug Resist. 2016;Volume 6(Issue 3):272–86.
114. African Programme for Onchocerciasis Control (APOC)Strategic options and alternative treatment strategies for accelerating onchocerciasis elimination in Africa. Ouagadougou: World Health Organization2015.